Philippe Bishop

Title: Innovations of Philippe Bishop in Immunotherapy

Introduction

Philippe Bishop is an innovative inventor based in Las Vegas, NV (US). He has made significant contributions to the field of immunotherapy, particularly through his groundbreaking patent. His work focuses on enhancing the control of chimeric antigen receptor (CAR)-related immunotherapies.

Latest Patents

Philippe Bishop holds a patent for an "Aptamer-based CAR T-cell switch." This technology provides an aptamer-based switch that enhances the control of CAR-related immunotherapies. The system utilizes a synthetic bridge molecule that contains a target-binding aptamer linked to a CAR-binding aptamer. This innovative platform allows for targeted immunotherapy, enabling the system to be directed to any desired antigen by selecting the appropriate target-binding aptamer. It also offers the flexibility to switch targets, adjust dosages according to patient needs, and integrate with both in vivo and ex vivo CAR expression. Notably, this technology is non-immunogenic and has low production costs. Philippe Bishop has 1 patent to his name.

Career Highlights

Philippe Bishop is currently associated with Alaya.bio Inc., where he continues to develop and refine his innovative technologies. His work has the potential to revolutionize the field of immunotherapy, providing new avenues for treatment and patient care.

Collaborations

Philippe collaborates with talented individuals such as Anna Miodek and Frédéric Mourlane, contributing to a dynamic research environment that fosters innovation and progress in the field.

Conclusion

Philippe Bishop's contributions to immunotherapy through his aptamer-based CAR T-cell switch exemplify the potential of innovative technologies in medicine. His work not only enhances treatment options but also paves the way for future advancements in the field.